By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Nabriva Therapeutics 

Leberstrasse 20

Vienna    1112  Austria
Phone: 43-0-1-74093-0 Fax: 43-0-1-74093-1900


Company News
Nabriva Raises $120 Million, Headed to Phase III for New Antibiotic 4/7/2015 5:50:04 AM
Nabriva Therapeutics Strengthens Board And Management Team 1/29/2015 10:51:08 AM
Nabriva Therapeutics Announces Qualified Infectious Disease Product And Fast Track Status Granted By The US FDA For Lefamulin 10/8/2014 9:16:26 AM
Nabriva Therapeutics Presented Data On Lead Pleuromutilin Antibiotic Lefamulin (BC-3781) At The 54th Interscience Conference On Antimicrobial Agents And Chemotherapy In Washington DC 9/8/2014 9:23:23 AM
Nabriva Therapeutics Appoints Dr. Colin Broom As CEO 9/3/2014 6:37:02 AM
Nabriva Therapeutics Presents Extended Spectrum Pleuromutilin Antibiotics At The 24th European Congress Of Clinical Microbiology And Infectious Diseases, Barcelona 5/12/2014 12:12:26 PM
Forest Laboratories, Inc. (FRX) Coughs Up $25 Million for Nabriva Therapeutics's Phase II Antibacterial, Right to Take Over Company 6/1/2012 6:42:35 AM
Nabriva Therapeutics Chooses TransPerfect Trial Interactive to Oversee Its Licensing Process 9/27/2011 10:42:28 AM
Nabriva Therapeutics Presents Extended Phase II Results for Pleuromutilin Antibiotic BC-3781 9/19/2011 10:33:08 AM
Nabriva Therapeutics Reports Positive Results from Phase II Trial of Pleuromutilin Antibiotic BC-3781 in ABSSSI 4/18/2011 10:48:33 AM